Company Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally.
The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023.
The company was founded in 2017 and is based in Zug, Switzerland.
| Country | Switzerland |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Riad Sherif |
Contact Details
Address: Bahnhofstrasse 20 Zug, 6300 Switzerland | |
| Phone | 41 41 711 3960 |
| Website | oculis.com |
Stock Details
| Ticker Symbol | OCS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| CIK Code | 0001953530 |
| ISIN Number | CH1242303498 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Riad Sherif M.B.A., M.D. | Chief Executive Officer and Director |
| Sylvia Cheung | Chief Financial Officer |
| Gudrun Bachmann Ph.D. | Chief Technology Officer |
| Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer |
| Daniel S. Char J.D. | Chief Legal Officer |
| Virginia R. Dean | Chief Human Resources Officer |
| Páll Ragnar Jóhannesson | Chief Business Officer |
| Rebecca Weil Ph.D. | Chief Commercial Officer |
| Dr. Snehal Shah Pharm.D. | President of Research and Development |
| Dr. Sharon Klier M.D., M.P.H. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | POS AM | Post-Effective amendments for registration statement |
| Dec 1, 2025 | 424B3 | Prospectus |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 10, 2025 | F-3 | Filing |
| Nov 10, 2025 | 6-K | Report of foreign issuer |
| Oct 31, 2025 | 424B5 | Filing |
| Oct 31, 2025 | 424B5 | Filing |
| Oct 31, 2025 | 6-K | Report of foreign issuer |
| Oct 29, 2025 | 6-K | Report of foreign issuer |
| Oct 9, 2025 | 144 | Filing |